文献速递皮肤肿瘤

咪喹莫特治疗恶性雀斑样痣与恶性雀斑样黑素瘤的系统综述:需标准化方案与结局指标

A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-01-23

完全临床清除率78.3%(369/471),组织学清除率77%(285/370),9例(1.8%)治疗后进展为恶性雀斑样黑素瘤。每周6-7次涂抹及总次数>60次与更高清除几率相关。

要点

  • 5%咪喹莫特治疗恶性雀斑样痣完全临床清除率78.3%,组织学清除率77%。
  • 每周6-7次涂抹较1-4次涂抹完全临床清除几率为6.47倍(P=0.017)。
  • 总涂抹>60次较<60次组织学清除几率为7.75倍(P=0.001)。

核心结论

  • 每周6-7次涂抹且总次数至少60次的咪喹莫特方案获得完全临床和组织学清除的几率最高。
  • 咪喹莫特是适合或不适合手术或放疗患者的治疗选择。
  • 9例恶性雀斑样痣治疗后短期进展为恶性雀斑样黑素瘤,假说认为这些黑素瘤可能在治疗前已存在。

研究设计与样本

  • 系统综述检索PubMed、EMBASE和Cochrane图书馆自建库至2015年5月。
  • 纳入描述组织学证实的恶性雀斑样痣接受5%咪喹莫特单药或联合其他局部治疗的研究。
  • 质量评估采用类GRADE清单,结果按PRISMA声明报告。

主要发现

  • 完全临床清除见于471例中的369例(78.3%)。
  • 组织学清除见于370例中的285例(77%)。
  • 9例(1.8%)在治疗后3.9个月(范围0-11个月)诊断为恶性雀斑样黑素瘤。
  • 每周6-7次涂抹较1-4次涂抹完全临床清除的比值比为6.47(P=0.017)。
  • 每周6-7次涂抹较1-4次涂抹组织学清除的比值比为8.85(P=0.003)。

关键数值与推荐

  • 完全临床清除率78.3%(369/471)。
  • 组织学清除率77%(285/370)。
  • 恶性雀斑样黑素瘤诊断率1.8%(9例),诊断时间治疗后3.9个月(范围0-11个月)。
  • 每周6-7次涂抹较1-4次涂抹完全临床清除OR=6.47(P=0.017)。
  • 每周6-7次涂抹较1-4次涂抹组织学清除OR=8.85(P=0.003)。

临床怎么用

  • 对不适合或不愿接受手术或放疗的恶性雀斑样痣患者,可考虑5%咪喹莫特治疗。
  • 推荐采用每周6-7次涂抹、总次数至少60次的治疗方案以提高清除几率。
  • 治疗期间及治疗后需监测疾病进展为恶性雀斑样黑素瘤的可能。

局限性

  • 研究设计异质性大,以病例报告和回顾性研究为主,仅1项随机对照试验。
  • 治疗方案和结局评估缺乏标准化。
  • 进展为恶性雀斑样黑素瘤的病例可能在治疗前已存在,无法排除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lentigo maligna (LM) is an in situ variant of melanoma. Our objective was to systematically review clinical and histological clearance and recurrence rates of imiquimod treatment of LM with emphasis on progression to lentigo maligna melanoma (LMM). PubMed, EMBASE and the Cochrane library were searched from inception to May 2015. Articles were included if they described histologically proven LM treated with imiquimod 5% monotherapy or combined with another topical therapy. Analysed outcomes were clinical and histological clearance, recurrence rates and number of LMM. The quality was assessed using the GRADE-like checklist, and results were reported according to the PRISMA Statement. Twenty-six case reports, 11 retrospective studies, three prospective studies and one randomized controlled trial were included. One case report of poor quality was excluded. Complete clinical clearance was seen in 369 of 471 patients (78.3%). Histological clearance was present in 285 of 370 (77%) patients. LMM was diagnosed in nine (1.8%) patients 3.9 months (range 0-11 months) post-treatment. Univariate multinominal logistic regression showed that 6-7 applications/week had a 6.47 greater odds (P = 0.017) of resulting in complete clinical clearance compared to 1-4 applications/week. An intensity of 6-7 applications/week showed a 8.85 greater odds (P = 0.003) of resulting in histological clearance compared to 1-4 applications. Applying imiquimod >60 times during a treatment period of 12 weeks (range 4-36) showed a 7.75 greater odds (P = 0.001) of resulting in histological clearance compared to <60 total applications. In conclusion, a treatment schedule using imiquimod 6-7 applications per week, with at least 60 applications, shows the greatest odds of complete clinical and histological clearance of LM. Imiquimod is an option for patients unfit for or not willing to undergo surgery or radiotherapy. Nine cases of LM progressed to LMM shortly after treatment. Our hypothesis is that these LMM may have been present before starting imiquimod.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Tio D, van der Woude J, Prinsen CAC, et al. A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures. J Eur Acad Dermatol Venereol. 2017. PMID: 27987308. doi:10.1111/jdv.14085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。